Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-105069
Filing Date
2025-08-07
Accepted
2025-08-07 16:22:14
Documents
53
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q janx-20250630.htm   iXBRL 10-Q 2592227
2 EX-10.1 janx-ex10_1.htm EX-10.1 43404
3 EX-31.1 janx-ex31_1.htm EX-31.1 18263
4 EX-32.1 janx-ex32_1.htm EX-32.1 10083
5 GRAPHIC img14736707_0.jpg GRAPHIC 14300
  Complete submission text file 0000950170-25-105069.txt   9875440

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT janx-20250630.xsd EX-101.SCH 1047118
55 EXTRACTED XBRL INSTANCE DOCUMENT janx-20250630_htm.xml XML 2102825
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)